A Delaware court has denied a motion from Spectrum Medical Partners Holdings, Inc. to reconsider a previous order regarding their former CEO, Dr. Krishnan Nagda. The ruling affects both parties involved in ongoing litigation in Florida and Delaware. This case highlights the complexities of enforcing judgments across state lines and the legal nuances involved in corporate governance.
The dispute began when Spectrum Medical Partners filed a lawsuit against Dr. Nagda in Florida, claiming breaches of contract and fiduciary duty, among other business torts. After winning a summary judgment in that case, which is currently under appeal, Spectrum sought to enforce that judgment in Delaware. The court's decision is significant as it clarifies the conditions under which enforcement of a foreign judgment can be stayed.
Background
Spectrum Medical Partners Holdings, Inc. is a healthcare company that previously employed Dr. Krishnan Nagda as its CEO. In September 2021, Spectrum initiated legal action against Dr. Nagda in Florida, alleging that he breached his contractual obligations and fiduciary duties. Following a favorable ruling in May 2025, Spectrum's victory is now subject to an appeal by Dr. Nagda.
In addition to the Florida lawsuit, Dr. Nagda filed a separate appraisal action in the Delaware Court of Chancery in November 2024, seeking to appraise his shares in Spectrum. This action has been stayed pending the outcome of the Florida litigation, creating a complex legal situation involving multiple jurisdictions.
The Ruling
On November 17, 2026, the Superior Court of Delaware ruled on Spectrum's motion for reconsideration regarding an earlier order from Commissioner Lynne M. Parker. The court denied Spectrum's request, stating, "The Commissioner acted within her discretion in imposing appropriate conditions on Defendant to protect Plaintiff’s interest and in granting Defendant’s Motion staying execution of attachment of the Chancery Action." This ruling emphasizes the court's support for the Commissioner’s decision to prevent Dr. Nagda from selling or transferring his shares in Spectrum while the appeal is pending.
The court also noted that the conditions set by the Commissioner provided sufficient protection for Spectrum's interests, stating, "Preventing alienation of the stock, directly or indirectly, protects Plaintiff’s interest." The ruling indicates that the court believes the measures taken were appropriate and necessary to ensure fairness in the ongoing litigation.
Impact
This ruling has significant implications for both parties involved. For Spectrum Medical Partners, the denial of the motion for reconsideration means that they must continue to navigate the complexities of the legal system while their appeal in Florida is pending. The court's decision reinforces the importance of adhering to the legal standards required for enforcing judgments across state lines.
For Dr. Nagda, the ruling allows him to maintain his interest in the appraisal action without the immediate threat of losing his shares in Spectrum. This decision may also influence how similar cases are handled in the future, particularly in terms of the enforcement of foreign judgments and the rights of defendants in ongoing litigation.
What's Next
The case may still be appealed further, particularly by Spectrum, as they continue to seek enforcement of their judgment against Dr. Nagda. Additionally, the related appraisal action in the Delaware Court of Chancery remains stayed, pending the outcome of the appeal in Florida. Details were not available in the court filing regarding any future hearings or timelines.
Read Next
Delaware court rules on LG Electronics vs. Invention Fund case
Delaware court denies Azzure Horsey’s postconviction relief
Court orders restitution in HOA embezzlement case
Vermont court denies motion to amend wrongful death complaint
Vermont court dismisses eviction case against Catherine Morrill
Vermont court rules on timber harvest dispute case









